更公司 查老板 童关系 查风险 都 在 用 的 商 业 查 词 工 具 (× 云南白药集团股份有限公司 天眼一下 国家中小企业发展子基金旗下机构 基本信息 217 上市信息 999+ 法律诉讼 413 经营风险 81 经营信息 999+ 主要股东 2 ● 品股权结构 股权变更历程140 ? 最新公示3 工商登记5 历史主要股东2 序号 股份类型 股东名称 云南省国有股权运营管理有限公司 器 1 流通A股 大股东 | 圆 省管国企 新华都实业集团股份有限公司 品 2 流通A股 大股东 云南合和（集团）股份有限公司 器 3 流通A股 大股东 | 国有独资 每经AI快讯，天眼查工商信息显示，近日，云南白药（000538）发生工商变更，董明卸任法定代表人，王明辉卸任董事长，由张文学接任，注册资本由约 10.4亿元人民币增至约17.8亿元人民币，同时，多位高管发生变更。云南白药集团股份有限公司成立于1993年11月，经营范围含化学原料药、化学药制剂、 中成药、中药材、生物制品、医疗器械等的销售，信息技术、科技及经济技术咨询服务，货物进出口等。股东信息显示，该公司由云南省国有股权运营管理 有限公司、新华都（002264） ...

据交易所数据显示，截至2025年12月5日收盘，云南白药（000538）报收于55.93元，上涨0.36%，换手 率0.27%，成交量4.72万手，成交金额2.64亿元。 资金流向方面，今日主力资金净流入4330.81万元，占比成交额16.43%。其中，超大单净流入228.63万 元、占成交额0.87%，大单净流入4102.18万元、占成交额15.56%，中单净流出流出1617.16万元、占成 交额6.13%，小单净流出2713.66万元、占成交额10.29%。 天眼查商业履历信息显示，云南白药集团股份有限公司，成立于1993年，位于昆明市，是一家以从事医 药制造业为主的企业。企业注册资本104139.9718万人民币，实缴资本43884.2484万人民币。公司法定代 表人为董明。 通过天眼查大数据分析，云南白药集团股份有限公司共对外投资了35家企业，参与招投标项目5000次， 知识产权方面有商标信息2375条，专利信息543条，此外企业还拥有行政许可1240个。 来源：市场资讯 云南白药最新一期业绩显示，截至2025三季报，公司营业总收入306.54亿元、同比增长2.47%，归属净 利润47.77亿元，同比 ...

Core Insights - Yunnan Baiyao has transformed from a traditional Chinese medicine brand into a modern pharmaceutical group, achieving significant growth in revenue and net profit over the past 32 years since its listing [2] - The company emphasizes strategic focus and product quality as keys to success in a changing external environment [2] Financial Performance - Revenue increased from 0.58 billion to 40.033 billion, a growth of 690 times; net profit rose from 0.13 billion to 4.749 billion, a growth of 365 times [2] - In the first three quarters of 2025, Yunnan Baiyao achieved revenue of 30.654 billion, a year-on-year increase of 2.47%, and net profit of 4.777 billion, a year-on-year increase of 10.41% [4] Digital Transformation - The company has implemented a comprehensive digital transformation across its entire supply chain, establishing a "Smart Cloud Medicine" platform to enhance quality control and traceability of traditional Chinese medicinal materials [4][6] - The smart factory has reduced production process switching time from 20 minutes to 1 minute and active ingredient testing time from 710 minutes to 2 minutes [3] Industry Challenges - The traditional Chinese medicine industry faces challenges such as unstable quality and price volatility due to the agricultural nature of medicinal materials [3] - Yunnan Baiyao is addressing these issues by controlling quality from the seed level and ensuring traceability throughout the production process [5][6] Strategic Focus - The company is focusing on its core business of traditional medicine while also innovating in the pharmaceutical sector, aiming to create a competitive edge through continuous R&D investment [8] - Yunnan Baiyao's strategic planning includes three development curves: short-term focus on major traditional medicine products, mid-term innovation in traditional medicine and new transdermal preparations, and long-term development of nuclear medicine [9] Market Position - In the first half of 2025, the sales revenue from pharmaceuticals and health products reached 8.504 billion, accounting for 40.01% of total revenue, marking an 11.13% year-on-year increase [9]

Group 1 - Dongyangguang Pharmaceutical's total revenue from 2022 to 2024 is projected to reach 14.2 billion, with R&D investment of 2.5 billion over the past three years, and operating profit exceeding 2.1 billion in the last two years [21] - Huaren Sanjiu's R&D investment is expected to reach 950 million in 2024, a 63.97% increase from 2020, with R&D personnel increasing to 876, more than double that of 2020 [21] - Yunnan Baiyao achieved a net profit of 4.777 billion in the first three quarters of 2025, a year-on-year increase of 10.41%, surpassing the full-year profit of 4.749 billion in 2024, marking a historical high for the same period [21] Group 2 - Yunnan Baiyao emphasizes the importance of returning to its core business and focusing on continuous effective R&D investment to build a competitive moat [22] - Huaren Sanjiu is accelerating its merger and integration pace, focusing on consumer health, medical health, and elderly health sectors, while enhancing R&D investment to drive innovation transformation [22] - Dongyangguang Pharmaceutical has developed three self-researched new drugs and has nearly 50 new drugs in the pipeline, actively seeking international markets for growth [26][31] Group 3 - Yanhuilong has invested over 1 billion in R&D from 2021 to 2024, with annual R&D investment accounting for over 20% of its main business revenue [21][51] - The company is shifting from rapid market capture to deep innovation, focusing on high-quality development and establishing a unique project advantage in the IVD industry [49][50] - Yanhuilong's overseas revenue exceeded 200 million in the first three quarters, a nearly 40% year-on-year increase, indicating successful market expansion [54] Group 4 - Yunnan Baiyao's revenue has grown from 58 million to 40.033 billion over 32 years, a 690-fold increase, with net profit rising from 1.3 million to 4.749 billion, a 365-fold increase [40] - The company has established a digital transformation strategy, creating a full-chain digital system to enhance operational efficiency and product quality [41][42] - Yunnan Baiyao's strategic planning includes three R&D curves focusing on traditional Chinese medicine, innovative drugs, and nuclear medicine [48] Group 5 - Dongyangguang Pharmaceutical has built a comprehensive R&D system and a modern factory with an annual production capacity of 1.8 billion tablets [29] - The company is actively integrating AI into drug discovery processes to enhance efficiency and reduce costs [30] - Huaren Sanjiu's revenue is projected to reach 27.6 billion in 2024, a 102% increase from 2020, with a compound annual growth rate of 23.6% in revenue and 24.5% in profit over the past three years [35]

Core Viewpoint - The Chinese traditional medicine sector is experiencing increased activity due to a surge in flu cases, with the Chinese Medicine ETF (560080) showing a slight decline but still attracting investor interest [1][9]. Market Performance - The Chinese Medicine ETF (560080) closed down 0.91% today, remaining in a consolidation phase, with a trading volume exceeding 84 million yuan, a 7% increase from the previous trading day [1]. - The ETF's closing premium rate was 0.06%, indicating ongoing investor attention, with two out of the last five days seeing inflows [1]. - The ETF's latest scale reached 2.598 billion yuan, leading its peers in the same category [1]. Stock Performance - Most constituent stocks of the Chinese Medicine ETF closed in the red, with notable declines including: - Pianzaihuang down 1.59% to 168.75 yuan, marking a five-year low [3]. - Yiling Pharmaceutical down over 3%, and Zhongsheng Pharmaceutical down over 2% [3]. - Conversely, stocks like Yunnan Baiyao and Jilin Aodong saw slight increases [3]. Valuation Metrics - As of December 3, the TTM price-to-earnings (PE) ratio for the ETF's index was 25.12, positioned at the 23.11% percentile over the past decade, suggesting that the index is cheaper than 76% of the time historically [5]. - The TTM PE is just 0.38 away from the calculated opportunity value, indicating a potential entry point for investors [5]. Historical Performance - The year-to-date return for the Chinese Medicine Index remains negative at -2.24%, with a decline of 8.13% projected for 2024 [7]. - The index has shown a pattern of consecutive declines, with four consecutive negative years if 2023 is considered a down year [7]. Demand Drivers - The recent flu outbreak has led to a significant increase in demand for respiratory medications, with flu cases reported rising by 53.8% compared to the previous week [9]. - The flu activity is at its highest level since 2022, which is expected to boost the demand for related medications [9]. Industry Outlook - Analysts from Zheshang Securities predict an inflection point for the Chinese medicine sector, suggesting that the sector will attract more investment due to its stable cash flow and lower volatility compared to other sectors [9]. - The industry is expected to see improved revenue and net profit growth in the second half of 2025, aided by reduced cost pressures from declining raw material prices [9].

Personnel Changes - Yunnan Baiyao announced the election of Zhang Wenxue as chairman and Dong Ming as vice chairman during the first meeting of the 11th board of directors on November 10, 2025 [2] - China National Pharmaceutical Group (Sinopharm) reported the resignation of Zhao Bingxiang from multiple positions, including non-executive director and chairman, with Jin Bin proposed as the new chairman [3] - Huatai Medical announced a board restructuring, nominating several candidates for its third board of directors, including current executives from Mindray Medical [4] - Hanyu Pharmaceutical reported the retirement of its executive director Pinxiang Yu and appointed two new executive directors, Shen Yaping and Tang Yangming [5] - GSK China appointed Sheng Feng as vice president, responsible for market access and commercial operations, effective December 1, 2025 [12] Executive Appointments - Medtronic appointed Larry Xu as vice president for orthopedic and neurosurgery business in China, effective November 10, 2025 [9] - Pfizer China announced the appointment of Su Tianyu as head of the broad market division, effective immediately [10][11] - Eli Lilly appointed Carole Ho as president of the neuroscience division, while Adrienne Brown was promoted to president of the immunology division [15] - Restore Medical appointed Chris Cleary, former senior vice president at Medtronic, as chairman of the board [18] Resignations - Johnson & Johnson announced the departure of Alex He, vice president and head of the PINS division, effective December 31, 2025 [8] - Several executives across various companies, including Chen Changbing from Sinopharm United and Wang Junbo from Guangyu Yuan, submitted their resignations due to work adjustments [3][5]

Core Insights - A total of 21 buy ratings were issued by institutions today, covering 20 stocks, with Guizhou Moutai receiving the highest attention with two buy ratings [1][2] - Among the rated stocks, 11 provided future target prices, with 7 stocks showing an upside potential exceeding 20%, led by Guizhou Moutai with a target price of 2600.00 CNY, indicating a potential increase of 79.56% [1][2] - The average increase for stocks with buy ratings today was 0.82%, outperforming the Shanghai Composite Index, with notable gainers including Hu Guang Co., Sophia, and Shenzhou Digital [1][2] Company Summaries - Guizhou Moutai received a strong buy rating from Huachuang Securities with a target price of 2600.00 CNY, compared to the latest closing price of 1448.00 CNY [2] - Dongpeng Beverage also received a strong buy rating from Huachuang Securities with a target price of 340.00 CNY, latest closing at 269.03 CNY [2] - Shenzhou Digital was rated as "Increase" by Guotai Junan with a target price of 55.97 CNY, latest closing at 41.27 CNY [2] - Hu Guang Co. was rated as "Strong Buy" by Huachuang Securities with a target price of 37.90 CNY, latest closing at 31.30 CNY [2] - Other notable stocks include Jerry Shares, which was rated "Increase" with a target price of 73.20 CNY, latest closing at 62.07 CNY [2] Industry Insights - The basic chemical industry was the most favored, with stocks like Huhua Co. and Chuanheng Co. receiving buy ratings [2] - The computer and automotive industries also attracted attention, with two stocks each receiving buy ratings [2]

Core Viewpoint - Yunnan Baiyao's net profit attributable to shareholders reached 4.777 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 10.41% [1] - The company reported a net profit of 1.144 billion yuan in Q3 2025, showing a slight year-on-year growth of 0.55% [1] Group 1: Financial Performance - The industrial revenue for the first three quarters of 2025 was 11.582 billion yuan, representing a year-on-year increase of 8.48% [1] - The core product of the pharmaceutical business group, Yunnan Baiyao aerosol, achieved sales revenue exceeding 1.453 billion yuan in H1 2025, marking a significant growth of over 20.9% [1] Group 2: Strategic Developments - The company completed a special dividend to reward shareholders, indicating a commitment to returning value [1] - Yunnan Baiyao is actively pursuing a second growth curve by enhancing its traditional Chinese medicine pipeline through the acquisition of Juyaotang and continuing research and development in both traditional and innovative medicines [1]

Group 1 - The core viewpoint of the news highlights the strong performance of the Traditional Chinese Medicine (TCM) sector, driven by supportive government policies aimed at innovation and industrial transformation [1][2] - The Shanghai government has issued a document encouraging collaboration among medical institutions, research units, and pharmaceutical companies to create platforms for TCM innovation and industrial transformation [1] - The document supports the development of major TCM varieties and the secondary development of classic varieties, as well as the establishment of mechanisms for collecting and organizing human experience data for drug registration [1] Group 2 - China Galaxy Securities anticipates that policy-driven changes will continue to propel the pharmaceutical industry towards innovation and upgrades, with a focus on finding incremental opportunities in niche markets [2] - The report indicates that domestic innovative drugs are expected to yield results, with several second-generation I/O drugs and ADCs entering phase three clinical trials, which is promising for future developments [2] - The TCM prescription drug market is facing clinical re-evaluation, which may reshape the market landscape and potentially lead to a turning point in TCM gross margins [2] Group 3 - The TCM ETF closely tracks the Zhongzheng TCM Index, which selects listed companies involved in TCM production and sales to reflect the overall performance of TCM concept stocks [2] - As of October 31, 2025, the top ten weighted stocks in the Zhongzheng TCM Index account for 54.92% of the index, including companies like Yunnan Baiyao and Tongrentang [2]

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical segment achieved a revenue of CNY 4.751 billion, representing a year-on-year growth of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded CNY 1.453 billion, with a significant year-on-year increase of over 20.9% [2] - Other traditional Chinese medicine products showed remarkable growth, with sales of Canling Jianpi Granules exceeding CNY 100 million and Pudilan Anti-inflammatory Tablets nearing CNY 100 million [2] - Plant-based products, such as Qixue Kang Oral Liquid, reached sales of CNY 202 million, with a year-on-year growth of approximately 116.2% [2] Group 2: Nuclear Medicine R&D Progress - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 22 activated, enrolling 60 subjects [3] - The INR102 therapeutic nuclear medicine project has received a clinical trial notification, with Phase I trials underway and 12 patients enrolled for Phase II trials [3] Group 3: Health Products Business Performance - The health products segment reported a revenue of CNY 3.442 billion in the first half of 2025, reflecting a year-on-year growth of 9.46% [4] - The segment focuses on a full-channel operation strategy, enhancing offline distribution capabilities and increasing online channel investments [4] - The oral care category, particularly gum care toothpaste, maintains and gradually expands its leading advantage, while anti-sensitivity toothpaste shows breakthrough growth [4] Group 4: Online Sales Performance - The pharmaceutical segment's online sales increased by over 20% year-on-year, with a GMV of CNY 254 million generated from 4.845 million visitors [5] - Yunnan Baiyao toothpaste holds the top market share in the domestic all-channel market, while Yangyuanqing shampoo ranked first in Tmall's domestic anti-hair loss category during the 2025 "618" shopping festival [5] Group 5: Dividend Distribution - For the 2024 fiscal year, the company distributed a cash dividend of CNY 11.85 per 10 shares, totaling CNY 2.164 billion [6] - The total cash dividend for 2024, including special dividends, amounted to CNY 23.98 per 10 shares, representing 90.09% of the net profit attributable to shareholders [7] - In the first half of 2025, the company distributed a cash dividend of CNY 10.19 per 10 shares, totaling CNY 1.818 billion, with special dividends accounting for 50.05% of the net profit for the period [7]